1
|
Berger T, Adamczyk-Sowa M, Csépány T, Fazekas F, Fabjan TH, Horáková D, Ledinek AH, Illes Z, Kobelt G, Jazbec SŠ, Klímová E, Leutmezer F, Rejdak K, Rozsa C, Sellner J, Selmaj K, Štouracˇ P, Szilasiová J, Turcˇáni P, Vachová M, Vanecková M, Vécsei L, Havrdová EK. Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease. Ther Adv Neurol Disord 2020; 13:1756286420975223. [PMID: 33335562 PMCID: PMC7724259 DOI: 10.1177/1756286420975223] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Accepted: 10/23/2020] [Indexed: 12/23/2022] Open
Abstract
At two meetings of a Central European board of multiple sclerosis (MS) experts in
2018 and 2019 factors influencing daily treatment choices in MS, especially
practice guidelines, biomarkers and burden of disease, were discussed. The
heterogeneity of MS and the complexity of the available treatment options call
for informed treatment choices. However, evidence from clinical trials is
generally lacking, particularly regarding sequencing, switches and escalation of
drugs. Also, there is a need to identify patients who require highly efficacious
treatment from the onset of their disease to prevent deterioration. The recently
published European Committee for the Treatment and Research in Multiple
Sclerosis/European Academy of Neurology clinical practice guidelines on
pharmacological management of MS cover aspects such as treatment efficacy,
response criteria, strategies to address suboptimal response and safety concerns
and are based on expert consensus statements. However, the recommendations
constitute an excellent framework that should be adapted to local regulations,
MS center capacities and infrastructure. Further, available and emerging
biomarkers for treatment guidance were discussed. Magnetic resonance imaging
parameters are deemed most reliable at present, even though complex assessment
including clinical evaluation and laboratory parameters besides imaging is
necessary in clinical routine. Neurofilament-light chain levels appear to
represent the current most promising non-imaging biomarker. Other immunological
data, including issues of immunosenescence, will play an increasingly important
role for future treatment algorithms. Cognitive impairment has been recognized
as a major contribution to MS disease burden. Regular evaluation of cognitive
function is recommended in MS patients, although no specific disease-modifying
treatment has been defined to date. Finally, systematic documentation of
real-life data is recognized as a great opportunity to tackle unresolved daily
routine challenges, such as use of sequential therapies, but requires joint
efforts across clinics, governments and pharmaceutical companies.
Collapse
Affiliation(s)
- Thomas Berger
- Department of Neurology, Medical University of Vienna, Waehringer Guertel 18-20, Vienna 1090, Austria
| | - Monika Adamczyk-Sowa
- Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
| | - Tünde Csépány
- Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
| | - Franz Fazekas
- Department of Neurology, Medical University of Graz, Graz, Austria
| | - Tanja Hojs Fabjan
- Department of Neurology, University Medical Centre Maribor, Maribor, Slovenia
| | - Dana Horáková
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
| | | | - Zsolt Illes
- Department of Neurology, University of Southern Denmark, Odense, Denmark
| | | | - Saša Šega Jazbec
- Department of Neurology, University Clinical Centre Ljubljana, Ljubljana, Slovenia
| | - Eleonóra Klímová
- Department of Neurology, University of Prešov and Teaching Hospital of J. A. Reiman, Prešov, Slovakia
| | - Fritz Leutmezer
- Department of Neurology, Medical University of Vienna, Vienna, Austria
| | - Konrad Rejdak
- Department of Neurology, Medical University of Lublin, Lublin, Poland
| | - Csilla Rozsa
- Department of Neurology, Jahn Ferenc Dél-pesti Hospital, Budapest, Hungary
| | - Johann Sellner
- Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, Mistelbach, Austria, and Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria
| | - Krzysztof Selmaj
- Department of Neurology, University of Warmia-Mazury, Olsztyn, Poland
| | - Pavel Štouracˇ
- Department of Neurology, Masaryk University, Brno, Czech Republic
| | - Jarmila Szilasiová
- Department of Neurology, P. J. Šafárik University Košice and University Hospital of L. Pasteur Košice, Slovakia
| | - Peter Turcˇáni
- Department of Neurology, Comenius University, Bratislava, Slovakia
| | | | - Manuela Vanecková
- Department of Radiology, MRI Unit, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
| | - László Vécsei
- Department of Neurology and MTA-SZTE Neuroscience Research Group, University of Szeged, Szeged, Hungary
| | - Eva Kubala Havrdová
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
| |
Collapse
|
2
|
Ness NH, Haase R, Kern R, Schriefer D, Ettle B, Cornelissen C, Akguen K, Ziemssen T. The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study. J Med Internet Res 2020; 22:e17921. [PMID: 32181745 PMCID: PMC7109610 DOI: 10.2196/17921] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2020] [Revised: 02/18/2020] [Accepted: 02/19/2020] [Indexed: 02/06/2023] Open
Abstract
Background Survey-based studies are frequently used to describe the economic impact of multiple sclerosis (MS). However, there is no validated health resource survey available, preventing comparison of study results and meaningful conclusions regarding the efficiency of long-term treatments. Objective The aim of this study was to develop and validate a tablet- and paper-based MS health resource utilization survey. Methods We developed and validated the Multiple Sclerosis Health Resource Utilization Survey (MS-HRS), consisting of 24 cost items for paper and tablet users. Data for validation came from two large German observational studies. Survey practicability was assessed according to the response rate. Reliability was described using test-retest reliability as well as Guttman lambda. Construct validity was assessed as convergent and discriminant validity via correlations with associated patient-reported outcomes and known-group analyses. Results In total, 2207 out of 2388 (response rate: 92.4%) patients completed the survey and were included to determine psychometric properties. The test-retest reliability had an intraclass correlation coefficient of 0.828 over a course of 3 months. Convergent validity analyses showed that total costs correlated positively with increased disability (r=0.411, P<.001). For discriminant validity, correlations of total costs with the Treatment Satisfaction Questionnaire for Medication ranged from −0.006 (convenience) to −0.216 (effectiveness). The mean annual cost was €28,203 (SD €14,808) (US $39,203; SD US $20,583) with disease-modifying therapies. Conclusions The MS-HRS is a multilingual, reliable, valid, electronically available, and easy-to-administer questionnaire providing a holistic cross-sectional and longitudinal assessment of resource utilization in patients with MS.
Collapse
Affiliation(s)
| | - Rocco Haase
- University Hospital Carl Gustav Carus, Dresden, Germany
| | | | | | | | | | - Katja Akguen
- University Hospital Carl Gustav Carus, Dresden, Germany
| | | |
Collapse
|